Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...

41,366 people played the daily Crossword recently. Can you solve it faster than others?41,366 people played the daily Crossword recently. Can you solve it faster than others?

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...

Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression. J&J on Tuesday said the green ...

Stella Mental Health Westmont is a top depression and anxiety clinic near Chicago that offers comprehensive mental health treatments like Spravato (esketamine) therapy, ketamine infusion ...

Before Spravato was approved in 2019 ... per kilogram (kg) of body weight to 4.5 mg per kg of body weight. The initial dose for anesthesia induction is administered over several minutes. ...

Stella Mental Health Westmont is a top depression and anxiety clinic near Chicago that offers comprehensive mental health treatments like Spravato (esketamine) therapy, ketamine infusion ...